Gut Microbiome

A shift toward proteolytic gut fermentation links systemic inflammation to clinical phenotypes in major depressive disorder.

Niu M, Luo Y, et al. • Progress in neuro-psychopharmacology & biological psychiatry • 2026

PubMed 42636957 DOI 10.1016/j.pnpbp.2026.111900
TL;DR

MDD is characterized by a distinct 'gut-immune biotype' tightly linked to toxic proteolytic gut fermentation, with depletion of protective straight-chain SCFAs and elevation of branched-chain SCFAs correlating with systemic inflammation and clinical severity.

Key Findings

Results

MDD patients exhibited significant depletion of protective straight-chain SCFAs compared to healthy controls.

  • The study included 102 patients with MDD and 38 matched healthy controls.
  • Straight-chain SCFAs depleted in MDD included acetate, propionate, and butyrate.
  • These depletions indicate a pathological shift from saccharolytic to proteolytic fermentation in the gut.
  • Fecal SCFA profiles were quantified using laboratory measurement of fecal samples.
Results

MDD patients showed elevated branched-chain SCFAs (BSCFAs) relative to healthy controls.

  • Elevation in BSCFAs was identified as a marker of proteolytic gut fermentation in MDD.
  • The shift from saccharolytic to proteolytic fermentation was described as 'pathological.'
  • BSCFAs were among the key discriminating variables between MDD patients and controls.
  • This finding supports the existence of a gut-derived metabolic trigger in MDD pathophysiology.
Results

The metabolic shift toward proteolytic fermentation correlated with elevated systemic immune-inflammatory markers.

  • Elevated acute phase inflammatory index (API) and epidermal growth factor (EGF) were associated with the SCFA profile changes.
  • Serum immune-inflammatory markers were quantified alongside fecal SCFA profiles.
  • The correlation links gut-derived metabolic changes to systemic immune activation.
  • This pattern was interpreted as consistent with the NIMETOX (Neuro-Immune-Metabolic-Oxidative Stress) theoretical framework.
Results

A multidimensional model combining BSCFAs, acetate, API, and EGF discriminated MDD from controls with an AUC of 0.871.

  • The model was described as having 'adequate accuracy' for discrimination.
  • Binary logistic regression and linear discriminant analysis were used to evaluate joint discriminative performance.
  • The four-variable model included two gut metabolites (BSCFAs, acetate) and two immune markers (API, EGF).
  • AUC = 0.871 was achieved in a sample of 102 MDD patients and 38 controls.
Results

Elevated BSCFAs and decreased protective SCFAs were strongly associated with higher overall severity of depression (OSOD).

  • Multivariable regression models were applied to examine associations with clinical phenotypes.
  • OSOD (overall severity of depression) was one of three clinical phenotypes examined.
  • The associations persisted after multivariable adjustment.
  • The relationship suggests gut fermentation patterns track with depression symptom burden.
Results

Elevated BSCFAs and decreased protective SCFAs were strongly associated with more severe physiosomatic symptoms.

  • Physiosomatic symptoms were assessed as a distinct clinical phenotype separate from overall depression severity.
  • The association was identified using multivariable regression models.
  • Physiosomatic symptoms represent somatic manifestations accompanying depression.
  • This finding links gut fermentation patterns to somatic symptom burden in MDD.
Results

Elevated BSCFAs and decreased protective SCFAs were strongly associated with increased recurrence of illness (ROI) in MDD.

  • Recurrence of illness (ROI) was the third clinical phenotype examined.
  • Associations were assessed using multivariable regression models.
  • This finding suggests that proteolytic gut fermentation may be linked to a more recurrent course of MDD.
  • The association held after adjustment for other variables in the model.
Results

Use of 5-HT1A receptor agents was associated with higher BSCFA levels after adjustment for MDD status.

  • This association remained statistically significant after adjustment for MDD status.
  • 5-HT1A agents are a class of serotonin receptor-targeting medications used in depression treatment.
  • The finding was noted as a notable secondary observation in the study.
  • The direction of causality between 5-HT1A agent use and elevated BSCFAs was not established in this cross-sectional analysis.
Conclusions

The study proposed the concept of a 'gut-immune biotype' for MDD based on the combined SCFA and immune-inflammatory profile.

  • The biotype was defined by toxic proteolytic gut fermentation combined with systemic immune activation.
  • The authors frame this as 'a systems biology explanation for MDD.'
  • The gut-immune biotype concept is positioned within the broader NIMETOX theoretical framework.
  • The authors call for 'microbiome-targeted interventions in precision psychiatry' based on these findings.

What This Means

This research suggests that people with major depressive disorder (MDD) have a distinct pattern of gut bacteria activity compared to healthy individuals. Specifically, the gut bacteria of MDD patients appear to be breaking down proteins rather than carbohydrates, producing higher levels of branched-chain short-chain fatty acids (BSCFAs) and lower levels of normally protective compounds like acetate, propionate, and butyrate. This abnormal fermentation pattern was also linked to elevated markers of inflammation in the blood, suggesting the gut and the immune system are communicating in a way that may worsen depression. The study found that a combination of these gut and immune markers could distinguish MDD patients from healthy controls with reasonable accuracy (AUC = 0.871). More importantly, the degree of this gut fermentation imbalance tracked with how severe patients' depression was, how many physical symptoms they experienced, and how often their depression had recurred. The researchers also observed that patients using a certain class of antidepressants (5-HT1A agents) tended to have higher levels of the abnormal fermentation markers, even when accounting for having MDD itself. This research suggests that MDD may have a recognizable 'gut-immune fingerprint' that could one day help identify subtypes of depression and guide treatment choices. The findings point toward the potential value of interventions targeting the gut microbiome — such as dietary changes, probiotics, or prebiotics — as part of a broader treatment approach for depression. However, because this was a cross-sectional study comparing groups at a single point in time, it cannot establish whether gut changes cause depression or result from it, and further research is needed before these findings can be applied clinically.

Have a question about this study?

Presence or severity of Hashimoto's thyroiditis does not influence basal calcitonin levels: observations from CROHT biobank.
Journal of endocrinological investigation • 2022

HT patients of all disease stages preserve Ct production as healthy individuals and there is no need for Ct measurements...
Approach to the Patient: Safety of Growth Hormone Replacement in Children and Adolescents.
The Journal of clinical endocrinology and metabolism • 2022

rhGH therapy has been used for more than 3 decades and data are largely reassuring, yet we still have much to learn abou...
Extended Absorption of Liothyronine from Poly-Zinc-Liothyronine: Results from a Phase 1, Double-Blind, Randomized, and Controlled Study in Humans.
Thyroid : official journal of the American Thyroid Association • 2022

PZL possesses the necessary properties to achieve a much improved T3 pharmacokinetic profile, with ~30% lower Cmax that...
Lipoprotein subtypes after testosterone therapy in transmasculine adolescents.
Journal of clinical lipidology • 2022

Testosterone appears to be a major contributor to differences in lipoprotein profiles, a surrogate for cardiovascular di...
Long-term testosterone undecanoate treatment in the elderly testosterone deficient male: An observational cohort study.
Andrology • 2022

Long-acting testosterone undecanoate treatment in elderly testosterone-deficient patients required more frequent dose ad...
Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism.
Clinical endocrinology • 2022

The Society for Endocrinology commissioned a multidisciplinary guideline to provide all care providers with a comprehens...

Citation

Niu M, Luo Y, Yangyang C, Almulla A, Carvalho A, Li J, et al.. (2026). A shift toward proteolytic gut fermentation links systemic inflammation to clinical phenotypes in major depressive disorder.. Progress in neuro-psychopharmacology & biological psychiatry. https://doi.org/10.1016/j.pnpbp.2026.111900